Abstract
Rural persons with HIV face barriers to care that may influence adoption of advances in therapy. We performed a retrospective cohort study to determine rural–urban variation in adoption of raltegravir—the first HIV integrase inhibitor—in national Veterans Afffairs (VA) healthcare. There were 1,222 veterans with clinical indication for raltegravir therapy at time of its FDA approval in October 2007, of whom 223 (19.1%) resided in rural areas. Urban persons were more likely than rural to initiate raltegravir within 180 days (17.3% vs. 11.2%, P = 0.02) and 360 days (27.5% vs. 19.7%, P = 0.02), but this gap narrowed slightly at 720 days (36.3% vs. 31.8%, P = 0.19). In multivariable analysis adjusting for patient characteristics, urban residence predicted raltegravir adoption within 180 days (odds ratio 1.72, 95% CI 1.09–2.70) and 360 days (OR 1.63, 95% CI 1.13–2.34), but not 720 days (OR 1.26, 95% CI 0.84–1.87). Efforts are needed to reduce geographic variation in adoption of advances in HIV therapy.
Resumen
Personas en zonas rurales con VIH enfrentan barreras medicas que pueden influir la adopción de advances de terapia. Realizamos un estudio de cohorte restrospectivo para determiner la variaciòn en zonas rurales-urbanas y la adopcion de raltegravir-el primer inhibidor de la integrasa del VIH-en hospitales nacionales de la Administración de Veteranos (VA). Había un total de 1,222 veteranos con indicación clínica para la terapia de raltegravir en el momento que fue aprobada for la FDA en Octubre del 2007, de los cuales 223 (19.1%) residían en zonas rurales. Personas en zonas urbanas eran más propensos que personas en zonas rurales en iniciar raltegravir dentro de 180 días (17.3% vs. 11.2%, P = 0.02) y 360 días (27.5% vs. 19.7%, P = 0.02), pero esta diferencia se redujo ligeramente a 720 días (36.3% vs. 31.8%, P = 0.19). Usando un analisis multivariable y ajustando las características del paciente, residencia urbana predijo la adopción de raltegravir dentro de 180 dias (proporción de probabilidades 1.72, 95% de CI 1.09–2.70 y 360 dias (proporción de probabilidades 1.63, 95% CI 1.13–2.34), pero no en 720 días (proporción de probabilidades 1.26, 95% CI 0.84–1.87). Mas esfuerzos son necesario para reducir la variacion geograficos en los advances de terapia del VIH.
Similar content being viewed by others
References
ART Cohort Collaboration Authors. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9.
Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51–9.
Nieuwkerk PT, Gisolf EH, Reijers MH, et al. Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS. 2001;15(15):1985–91.
Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429–41.
Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–54.
Marelich WD, Johnston RK, Murphy DA, Callari T. HIV/AIDS patient involvement in antiretroviral treatment decisions. AIDS Care. 2002;14(1):17–26.
Sambamoorthi U, Moynihan PJ, McSpiritt E, Crystal S. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health. 2001;91(9):1474–81.
Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV cost and services utilization study. JAMA. 1999;281(24):2305–15.
Wilson IB, Landon BE, Ding L, et al. A national study of the relationship of care site HIV specialization to early adoption of highly active antiretroviral therapy. Med Care. 2005;43(1):12–20.
Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States HCSUS consortium HIV cost and services utilization. J Acquir Immune Defic Syndr. 2000;25(2):115–23.
Landon BE, Wilson IB, Cohn SE, et al. Physician specialization and antiretroviral therapy for HIV. J Gen Intern Med. 2003;18(4):233–41.
Heckman TG, Somlai AM, Peters J, et al. Barriers to care among persons living with HIV/AIDS in urban and rural areas. AIDS Care. 1998;10(3):365–75.
Heckman TG, Somlai AM, Kalichman SC, Franzoi SL, Kelly JA. Psychosocial differences between urban and rural people living with HIV/AIDS. J Rural Health. 1998;14(2):138–45.
Reif S, Golin CE, Smith SR. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care. 2005;17(5):558–65.
Schur CL, Berk ML, Dunbar JR, et al. Where to seek care: an examination of people in rural areas with HIV/AIDS. J Rural Health. 2002;18(2):337–47.
Public Health Strategic Healthcare Group. The State of Care for Veterans with HIV/AIDS. 1-1-2009. Department of Veterans Affairs. Ref Type: Report.
Saha S, Freeman M, Toure J, et al. Racial and ethnic disparities in the VA health care system: a systematic review. J Gen Intern Med. 2008;23(5):654–71.
VA Planning Systems Support Group. VA Station Databases. United States Department of Veterans Affairs. 8-16-2011. Ref Type: Electronic Citation.
Willig JH, Aban I, Nevin CR, et al. Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. AIDS Res Hum Retrovir. 2010;26(12):1279–85.
Backus LI, Gavrilov S, Loomis TP, et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16(6):775–83.
Rural Urban Commuting Area Codes. WWAMI rural health research center. 1-1-2010. 1-25-2010. Ref Type: Internet Communication.
West AN, Lee RE, Shambaugh-Miller MD, et al. Defining “rural” for veterans’ health care planning. J Rural Health. 2010;26(4):301–9.
Kressin NR, Chang BH, Hendricks A, Kazis LE. Agreement between administrative data and patients’ self-reports of race/ethnicity. Am J Public Health. 2003;93(10):1734–9.
Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care. 2006;44(8 Suppl 2):S52–60.
Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8):814–23.
Belperio PS, Mole LA, Boothroyd DB, Backus LI. Trends in uptake of recently approved antiretrovirals within a national healthcare system. HIV Med. 2010;11(3):209–15.
Cohn SE, Berk ML, Berry SH, et al. The care of HIV-infected adults in rural areas of the United States. J Acquir Immune Defic Syndr. 2001;28(4):385–92.
Rodgers EM. Diffusion of innovations. 5th ed. New York: The Free Press; 2003.
Ding L, Landon BE, Wilson IB, et al. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Int Med. 2005;165(6):618–23.
Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS. 2008;22(3):233–43.
Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–91.
Acknowledgments
The work reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health, Veterans Rural Health Resource Center-Central Region. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the United States government.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohl, M., Lund, B., Belperio, P.S. et al. Rural Residence and Adoption of a Novel HIV Therapy in a National, Equal-Access Healthcare System. AIDS Behav 17, 250–259 (2013). https://doi.org/10.1007/s10461-011-0107-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-011-0107-8